chartexchange

Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

GlobeNewswire Inc. | Nov 9, 2026 8:30 AM EST

FDA assigned a PDUFA goal date of June 25, 2027 FDA assigned a PDUFA goal date of June 25, 2027

Read original article